@whisky. Bingo on the CE application stuff. I also think the recent update to CE file will extend process to Q3 but could help them with getting CE as their accuracy improved a lot after algo improvements. Their patient set was challenging. I saw a competitor data online and they chose a narrow patient set to achieve their CE. If you look at the December investor presentation video their MARD was very good for a 38 yr patient and that was what convinced me to buy. The delays just crashed the stock. It also seems to me like the wired form factors get CE faster than the wireless version like the glucotrack from Israel.
News 
Market Data 
Discover 
